Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Tegafur


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Tegafur?

Tegafur is an investigational drug.

There have been 140 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are Fudan University, National Taiwan University Hospital, and Taiho Pharmaceutical Co., Ltd.

There is one US patent protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Tegafur
TitleSponsorPhase
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction AdenocarcinomaSun Yat-sen UniversityPhase 2
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2/Phase 3
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction CancOno Pharmaceutical Co. LtdPhase 3

See all Tegafur clinical trials

Clinical Trial Summary for Tegafur

Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur

See all Tegafur clinical trials

US Patents for Tegafur

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur ⤷  Try it Free Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same Protalix Ltd. (Carmiel, IL) ⤷  Try it Free
Tegafur ⤷  Try it Free Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL) ⤷  Try it Free
Tegafur ⤷  Try it Free Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) ⤷  Try it Free
Tegafur ⤷  Try it Free Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Try it Free
Tegafur ⤷  Try it Free Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance Evogene Ltd. (Rehovot, IL) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur European Patent Office EP2134373 2027-02-28 ⤷  Try it Free
Tegafur European Patent Office EP2839839 2027-02-28 ⤷  Try it Free
Tegafur Spain ES2662036 2027-02-28 ⤷  Try it Free
Tegafur Israel IL200578 2027-02-28 ⤷  Try it Free
Tegafur Israel IL219783 2027-02-28 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.